Study identifies prostate cancer–related disparities between Indigenous and non-Indigenous men in a universal health care system

Indigenous Peoples in Canada have higher illness rates and lower life expectancies than non-Indigenous Canadians. A new study reveals that Indigenous men in the country who have prostate cancer are being diagnosed with more advanced and more aggressive tumors than their non-Indigenous counterparts. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

To identify disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in Canada, a team led by Adam Kinnaird, MD, PhD, of the University of Alberta, examined data on 1,444,974 men who were screened for prostate cancer in 2014–2022 and were enrolled in the Alberta Prostate Cancer Research Initiative.

When they examined testing rates by postal code, the investigators found that men in Indigenous communities were less likely to have prostate-specific antigen (PSA) tests to detect prostate cancer than men outside of Indigenous communities (32 versus 46 PSA tests per 100 men aged 50–70 years within 1 year).

Also, among 6,049 men diagnosed with prostate cancer, Indigenous men were more likely to have PSA levels ≥10 ng/mL (48% versus 30%), stage II or higher cancer (65% versus 47%), and high-grade tumors (79% versus 64%) than non-Indigenous men. In addition, over a median follow-up of 3.3 years, Indigenous patients were 2.3-times more likely to experience cancer spread, or metastasis, than non-Indigenous patients.

“What is critical about this is that these results come from within a publicly funded universal health care system in which all peoples should have equal access to care,” said Dr. Kinnaird. “The findings are significant because they identify Indigenous men as a population at risk for more aggressive prostate cancer and potentially worse survival. Key infrastructure changes, including better access to primary care physicians, may help improve prostate cancer screening and identify men at earlier, and curable, stages of the disease.”

Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com

Full Citation:
“Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal healthcare system.” Alex Kiciak, Wayne Clark, Maxwell Uhlich, Angeline Letendre, Catalina Vasquez, Anais Medina Martin, Michael Kolinsky, Christopher Fung, Tarek A. Bismar, John Lewis, and Adam Kinnaird. CANCER; Published Online: July 10, 2023 (DOI: 10.1002/cncr.34812). 

URL Upon Publication: http://doi.wiley.com/10.1002/cncr.34812

Author Contact: Michael Brown, media strategist at the University of Alberta, at michael.brown@ualberta.ca or +1 780-977-1411.

About the Journal     
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow us on Twitter @JournalCancer.

About Wiley
Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world's most important challenges. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, Twitter, LinkedIn and Instagram.